UK Study Reveals No Additional Advantage of Surfactant Therapy in Severe Bronchiolitis Cases in Infants

Why It Matters

The result eliminates an ineffective, resource‑intensive intervention for critically ill infants, allowing clinicians to prioritize evidence‑based care and conserve ICU supplies. It also underscores the urgent need for new treatments and preventive measures against RSV‑driven bronchiolitis.

Key Takeaways

• Surfactant therapy showed no ventilation reduction
• Trial enrolled 232 infants across UK hospitals
• Safety profile remained acceptable with no adverse events
• RSV vaccine uptake could reduce severe bronchiolitis cases
• Future research to target inflammation, antiviral pathways

Pulse Analysis

Bronchiolitis remains the leading cause of infant hospitalisation in the United Kingdom, driven primarily by respiratory syncytial virus (RSV). Each winter, roughly 25,000 newborns are admitted, and about 1,000 require invasive mechanical ventilation, placing a heavy strain on neonatal intensive care units. Standard treatment is largely supportive—oxygen, fluids, and careful monitoring—because no pharmacologic agent has convincingly altered disease trajectory. The physiological similarity between RSV‑induced airway collapse and the surfactant deficiency seen in premature respiratory distress syndrome sparked interest in repurposing surfactant therapy for these critically ill infants.

The Bronchiolitis Endotracheal Surfactant Study (BESS), a multicentre, randomized controlled trial funded by UKRI, NIHR and Chiesi Farmaceutici, enrolled 232 infants on ventilators across England, Scotland and Northern Ireland between 2019 and 2024. Participants received a single dose of exogenous surfactant via endotracheal tube or standard care alone. Primary analysis showed no statistically significant reduction in ventilation days, and secondary outcomes—including length of stay and mortality—were unchanged. Importantly, the intervention was well tolerated; the trial reported no surfactant‑related adverse events, confirming its safety but not its efficacy in this setting.

The negative BESS outcome reshapes clinical practice by discouraging routine surfactant use for severe bronchiolitis, thereby preserving scarce ICU resources and focusing attention on more promising avenues. Ongoing maternal RSV vaccination programmes, now entering national rollout, aim to confer passive immunity to newborns and could dramatically lower severe case numbers. Researchers are also exploring targeted anti‑inflammatory agents, monoclonal antibodies, and novel antivirals that address the complex immune response underlying RSV infection. Collectively, these strategies promise to reduce the burden on pediatric intensive care and improve survival for the most vulnerable infants.